Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clomoxir SCHEMBL28319997 | 0.99 | ABCB11 (0.46) | ABCB11LMNAMAPTMAPK1HDAC3 | |
| SCHEMBL11206802 | 0.94 | MAPK1 (0.43) | ABCB11LMNAMAPTMAPK1HDAC3 | |
| SCHEMBL11203828 | 0.86 | MAPT (0.50) | MAPTMAPK1HDAC3HDAC4HDAC1 | |
| Clomoxir SCHEMBL1580449 | 0.86 | ABCB11 (0.45) | ABCB11LMNAMAPTMAPK1HDAC3 | |
| SCHEMBL11270686 | 0.85 | MAPT (0.49) | MAPTMAPK1HDAC3HDAC4HDAC1 | |
| SCHEMBL11268901 | 0.81 | LMNA (0.72) | ABCB11LMNAMAPTMAPK1HDAC3 | |
| SCHEMBL4731655 | 0.81 | LMNA (0.72) | ABCB11LMNAMAPTMAPK1HDAC3 | |
| SCHEMBL11272688 | 0.80 | ABCB11 (0.52) | ABCB11LMNAMAPTMAPK1HDAC3 | |
| SCHEMBL682291 | 0.80 | ABCB11 (0.71) | ABCB11LMNAMAPTMAPK1 | |
| SCHEMBL11200657 | 0.80 | HDAC1 (0.46) | ABCB11LMNAMAPTMAPK1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1555 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| CN-102600144-A | Roflumilast for the treatment of diabetes mellitus | NYCOMED GMBH | 2012-07-25 | — | — | CN | claimed |
| US-20110212072-A1 | Inhibitors of Fatty Acid Oxidation for Prophylaxis and Treatment of Diseases Related to Mitochondrial Dysfunction | MEDIGENE AG (DE) | 2011-09-01 | — | — | US | claimed |
| US-20110178172-A1 | Inhibitors of Carnitin-Palmitoyl-Tranferase-1 for the Treatment and prevention of disorders caused by delipidation of neural tissue | META-IQ APS (DK) | 2011-07-21 | — | — | US | claimed |
| EP-2310003-A1 | INHIBITORS OF CARNITIN-PALMITOYL-TRANSFERASE-1 FOR THE TREATMENT AND PREVENTION OF DISORDERS CAUSED BY DELIPIDATION OF NEURAL TISSUE | Meta-IQ APS (DK) | 2011-04-20 | — | — | EP | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-20100034796-A1 | Inhibitors of fatty acid oxidation for prophylaxis and treatment of diseases related to mitochondrial dysfunction | MEDIGENE AG (DE) | 2010-02-11 | — | — | US | claimed |
| WO-2009156479-A1 | INHIBITORS OF CARNITIN-PALMITOYL-TRANSFERASE-1 FOR THE TREATMENT AND PREVENTION OF DISORDERS CAUSED BY DELIPIDATION OF NEURAL TISSUE | META-IQ APS (DK) | 2009-12-30 | — | — | WO | claimed |
| EP-1635813-A4 | COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA | MERCK & CO INC (US) | 2009-07-01 | — | — | EP | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | TREADWAY JUDITH L (US) | 2003-01-02 | — | — | US | claimed |
| US-20020183369-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | DU BOIS DAISY JOE (US) | 2002-12-05 | — | — | US | claimed |
| US-6399601-B1 | ANTIDIABETIC AGENTS; NERVOUS SYSTEM DISORDERS; ANTICHOLESTEROL AGENTS | PFIZER INC. | 2002-06-04 | — | — | US | claimed |
| US-20020013268-A1 | Synergistic effect of a sulfonylurea and/or non-sulfonylurea Kchannel blocker, and a phosphodiesterase 3 type inhibitor | FRYBURG DAVID A (US) | 2002-01-31 | — | — | US | claimed |
| EP-1145717-A2 | Synergistic effect of a sulfonylurea and/or non-sulfonylurea K plus ATP channel blocker, and a phosphodiesterase 3 type inhibitor | Pfizer Products Inc. (US) | 2001-10-17 | — | — | EP | claimed |
| EP-1136071-A2 | Use of glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-09-26 | — | — | EP | claimed |
| EP-1088824-A2 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | claimed |
| EP-0025192-B1 | SUBSTITUTED OXIRANE CARBOXYLIC ACIDS, PROCESS FOR THEIR PREPARATION, THEIR USE AND MEDICINES CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1983-05-11 | — | — | EP | claimed |
| US-4324796-A | HYPOGLYCEMIC AGENTS, HYPOKETONEMIC AGENTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1982-04-13 | — | — | US | claimed |
| EP-0025192-A2 | Substituted oxirane carboxylic acids, process for their preparation, their use and medicines containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1981-03-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178172-A1 | Inhibitors of Carnitin-Palmitoyl-Tranferase-1 for the Treatment and prevention of disorders caused by delipidation of neural tissue | CPT1A, CPT1B, ACAT2 | ABCB11 1783/4885LMNA 2051/4885MAPT 550/4885 |
| US-20110212072-A1 | Inhibitors of Fatty Acid Oxidation for Prophylaxis and Treatment of Diseases Related to Mitochondrial Dysfunction | CPT1A, CPT2, ACOX1 | ABCB11 2925/4885LMNA 3388/4885MAPT 1601/4885 |
| US-20100034796-A1 | Inhibitors of fatty acid oxidation for prophylaxis and treatment of diseases related to mitochondrial dysfunction | CPT1A, CPT2, CPT1B | ABCB11 2356/4885LMNA 2830/4885MAPT 1990/4885 |
| US-20020183369-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | PYGL, PYGM, PYGB | ABCB11 817/4885LMNA 891/4885MAPT 797/4885 |
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | PYGL, PYGM, GYS2 | ABCB11 1620/4885LMNA 1245/4885MAPT 3518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.